KẾT QUẢ HOÁ TRỊ BỔ TRỢ PHÁC ĐỒ CÓ OXALIPLATIN TRONG UNG THƯ ĐẠI TRÀNG GIAI ĐOẠN II NGUY CƠ CAO VÀ III TẠI BỆNH VIỆN ĐA KHOA HÙNG VƯƠNG

Abstract

Objectives: Describe some clinical and laboratory characteristics of patients with high-risk stage II and III colon cancer receiving adjuvant oxaliplatin-containing regimen at Hung Vuong General Hospital. Evaluation of treatment results and some undesirable effects of the study group of patients. Subjects and research methods: 39 patients were diagnosed with colon cancer stage II with high risk factors and III, underwent radical surgery, and received adjuvant chemotherapy after surgery. oxaliplatin at Hung Vuong Hospital from July 2019 to February 2023. Results: Mean age of patients: 57.43, the lowest age is 31, the oldest is 78. Male/female is 14/25. The most common tumor site was the right colon, 48.7%, the Sigma colon 30.7%, the left colon 12.8%, the transverse colon 7.8% the least common. The highest proportion of adenocarcinoma of the prostate is 79.5%, and the rate of mucosal cancer is 20.5%. Stage III accounts for a higher rate of 56.4%, stage II has a high risk of 43.6%. Toxicity on the hematopoietic system leukopenia grade 1,2 and 3.4 were 25.6% and 15.4%, respectively. Thrombocytopenia grade 1,2 accounted for 12.8%, hemoglobin decreased 2.6%. Toxicity outside the hematopoietic system is uncommon: Peripheral neuritis grade 1,2 accounted for 17.9%. Hand-foot syndrome level 1,2 accounted for 41%, not recorded grade 3.4. The number of chemotherapy patients with XELOX regimen accounted for 66.7% with OS after 4 years was 84.6%, mFOXFOX 6 regimen accounted for 33.3% with OS at 4 years was 96.2%, with P of 0.192. Conclusion: The regimen gave good results and toxicity was within acceptable limits